- Home
- UCTT vs KNSA Comparison
UCTT vs KNSA Comparison
Compare UCTT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCTT | KNSA |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UCTT | KNSA |
|---|---|---|
| Price | $91.70 | $52.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $97.33 | $60.86 |
| AVG Volume (30 Days) | ★ 1.0M | 656.4K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $1,734,500,000.00 | $677,564,000.00 |
| Revenue This Year | $19.18 | $37.48 |
| Revenue Next Year | $17.36 | $17.87 |
| P/E Ratio | ★ N/A | $196.04 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $18.93 | $26.27 |
| 52 Week High | $88.50 | $59.87 |
Technical Indicators
Market Signals| Indicator | UCTT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 46.73 |
| Support Level | $23.89 | $40.67 |
| Resistance Level | N/A | $59.87 |
| Average True Range (ATR) | 5.57 | 2.01 |
| MACD | 0.15 | -0.88 |
| Stochastic Oscillator | 94.75 | 7.89 |
Price Performance
Historical ComparisonAbout UCTT Ultra Clean Holdings Inc.
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.